SCHEMBL24469871

SCHEMBL24469871

CNC(=O)c1ccc(-n2c(=O)c3c(n4ncc(Cc5ccccc5)c24)CN(C(=O)OC(C)(C)C)C(C)C3)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 1/20 0.34
LMNA P02545 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
HDAC1 Q13547 4/20 0.33
TP53 P04637 2/20 0.33
GPR119 Q8TDV5 2/20 0.33
BRD4 O60885 1/20 0.33
CREBBP Q92793 1/20 0.33
HDAC6 Q9UBN7 2/20 0.32
OPRM1 P35372 1/20 0.32
OPRD1 P41143 1/20 0.32
CRBN Q96SW2 1/20 0.32
KDM4E B2RXH2 1/20 0.32
PKM P14618 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.31
MEN1 O00255 1/20 0.31
CYP2C19 P33261 1/20 0.31
KMT2A Q03164 1/20 0.31
MAPT P10636 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24469994 0.91 LMNA (0.34) ADAM17LMNATDP1HDAC1TP53
SCHEMBL24469942 0.91 HDAC1 (0.40) LMNAHDAC1TP53GPR119KDM4E
SCHEMBL24469948 0.90 CHRM4 (0.37) ADAM17LMNAHDAC1GPR119
SCHEMBL24469914 0.89 GPR119 (0.33) GPR119OPRM1
SCHEMBL24469765 0.89 GPR119 (0.33) GPR119KDM4EPKMSMN1; SMN2MEN1
SCHEMBL24470090 0.89 GPR119 (0.32) GPR119SMN1; SMN2MEN1CYP2C19KMT2A
SCHEMBL24470113 0.88 GPR119 (0.32) GPR119
SCHEMBL24470117 0.86 GPR119 (0.33) HDAC1GPR119
SCHEMBL24469837 0.86 P2RX3 (0.41) ADAM17LMNATDP1HDAC1TP53
SCHEMBL24469941 0.85 HDAC1 (0.37) LMNAHDAC1HDAC6SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820773-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
US-11820773-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
US-20220169650-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-06-02 US disclosed
WO-2022115384-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2022-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169650-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL ADAM17 3186/4885LMNA 1680/4885TDP1 2353/4885
US-11820773-B2 Tricyclic compounds SLC10A1, PKD1, CEL ADAM17 3186/4885LMNA 1680/4885TDP1 2353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.